April 27 (Reuters) - Bristol-Myers Squibb Co:
* ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB
* ADVANTAGENE - COLLABORATION TO EVALUATE SAFETY, EFFICACY OF CO’S INVESTIGATIONAL GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY COMBINED WITH BRISTOL’S OPDIVO
* ADVANTAGENE - ITS INVESTIGATIONAL GMCI COMBINED WITH OPDIVO IS TO TREAT NEWLY DIAGNOSED MALIGNANT GLIOMA PATIENTS GETTING SURGERY WITH/WITHOUT TEMOZOLOMIDE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
